Interleukin Genetics launches PerioPredict

Interleukin Genetics has launched PerioPredict, the company's new version of the PST genetic risk test for periodontal disease.

The PerioPredict measures variations in the genes for interleukin-1 (IL-1), a key mediator of inflammation, and identifies those who are at an increased risk for more severe periodontal disease, according to the company. The new collection device uses a simple cheek swab. The new test also utilizes an expansion of previous genetic markers that covers ethnic groups, including Hispanic, African-American, and Asian, in addition to Caucasian.

The PerioPredict sample is sent to Interleukin Genetics, a Clinical Laboratory Improvement Amendments (CLIA)-certified genetics laboratory, for analysis. Test results are returned to the dentist in about two weeks.

PerioPredict was used in a recent study in the Journal of Dental Research (June 10, 2013), which the company says provided insights into the prevention of periodontal disease.

Nearly half of the adult population has periodontitis. Prevention and treatment of periodontitis contributes to the $108 billion spent annually in the U.S. on dental care, the company said.

PerioPredict will be available January 2014.

Page 1 of 206
Next Page